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Abstract
Osteoarthritis is one of the most frequent and disabling diseases of the elderly. Only few
genetic variants have been identified for osteoarthritis, which is partly due to large pheno-
type heterogeneity. To reduce heterogeneity, we here examined cartilage thickness, one of
the structural components of joint health. We conducted a genome-wide association study
of minimal joint space width (mJSW), a proxy for cartilage thickness, in a discovery set of
13,013 participants from five different cohorts and replication in 8,227 individuals from
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seven independent cohorts. We identified five genome-wide significant (GWS,
P50×10−8) SNPs annotated to four distinct loci. In addition, we found two additional loci
that were significantly replicated, but results of combined meta-analysis fell just below the
genome wide significance threshold. The four novel associated genetic loci were located
in/near TGFA (rs2862851), PIK3R1 (rs10471753), SLBP/FGFR3 (rs2236995), and TREH/
DDX6 (rs496547), while the other two (DOT1L and SUPT3H/RUNX2) were previously iden-
tified. A systematic prioritization for underlying causal genes was performed using diverse
lines of evidence. Exome sequencing data (n = 2,050 individuals) indicated that there were
no rare exonic variants that could explain the identified associations. In addition, TGFA,
FGFR3 and PIK3R1 were differentially expressed in OA cartilage lesions versus non-
lesioned cartilage in the same individuals. In conclusion, we identified four novel loci
(TGFA, PIK3R1, FGFR3 and TREH) and confirmed two loci known to be associated with
cartilage thickness.The identified associations were not caused by rare exonic variants.
This is the first report linking TGFA to human OA, which may serve as a new target for
future therapies.
Author Summary
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of chronic
disability in the western society affectingmillions of people. OA is a degenerative joint dis-
ease characterized by changes in all joint tissues, including cartilage, bone and synovium,
causing chronic pain and loss of function. There are no effective therapeutic treatments
available for OA and therefore finding novel biological pathways through genetic associa-
tion studies can open up new treatment options. The number of known DNA variants
associated with OA-risk is limited.
To identify new loci, we have performed a GenomeWide Association Study meta-anal-
ysis on cartilage thickness, one of the joint tissues affected in OA in a total sample of more
than 20,000 individuals from twelve cohorts. This analysis revealed six variants associated
with cartilage thickness, four of these being novel associations, including TGFA as the
most prominent one. A systematic prioritization for underlying causal genes, using diverse
lines of evidence, highlighted genes underlying the disease associations, including TGFA,
RUNX2 and PIK3R1. Large scale exome sequencing data (n = 2,050 individuals) indicated
that there were no rare exonic variants that could explain the identified associations. This
is the first report linkingTGFA to human OA, which may serve as a new target for future
therapies
Introduction
In spite of advances in the understanding of OA, the absence of effective therapeutic targets
demonstrates that a better comprehension of its causes and pathophysiological mechanisms is
needed. Since genome-wide genetic studies are hypothesis-free and do not suffer from the bias
of previous knowledge, they have the potential to identify novel biological pathways involved
in OA. The discovery of novel genes has the potential to identify novel treatment options. In
addition, more personalizedmedicine approaches for OA can be explored through prediction
of risk for disease as well as classification of disease subtypes.
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Heritability of hip OA has been estimated to be around 40–60%. However, to date only few
genetic variants have been successfully identified [1,2]. The reasons for finding only a modest
number of genetic loci associated with hip OA can be attributed partially to relatively modest
samples sizes in comparison to other complex diseases, such as myocardial infarction [3]. In
addition, phenotype heterogeneity is an important issue in OA genetics as this is well known to
reduce power to robustly detect signals. The problem of heterogeneity in genetic association
studies of OA has been highlighted before [4,5] and is exemplified by the fact that the definition
of the phenotype is a combination of bone and/or cartilage features as well as clinical com-
plaints. Moreover, there is growing consensus that OA can be divided into multiple sub-pheno-
types each with their own etiology and risk factors. For example, it has been demonstrated that
individuals with hip OA, where only cartilage degradation is involved (atrophic OA form), are
linked to a different systemic bone phenotype compared to individuals with OA where bone
formation is also present [6].
As a way to overcome this, we examined a quantitative trait, which is one of the structural
components of joint health, cartilage thickness, as a distinct phenotype.
Joint SpaceWidth (JSW) is considered to be a proxy for cartilage thickness measured on hip
radiographs. Minimal JSW (mJSW) has been shown to be a more reliable measure for hip joint
health compared to the classical Kellgren & Lawrence score [7]. Previously, we have demon-
strated that using only a modest discovery sample size (n = 6,000), we were able to successfully
identify a genome-wide significant association of theDOT1L locus with mJSW as well as hip
OA [1,8]. We now aimed to perform a more powerful analysis by combining data from five
studies in the discovery phase, and subsequent replication in seven additional studies, amount-
ing to a total sample size of 21,240 to identify new genes implicated in joint health using mJSW
as a proxy for cartilage thickness. Using whole exome sequence data from 2,050 individuals we
screened the discovered genes for potential functional variants. Subsequently we usedmultiple
approaches that leverage different levels of information to enforce evidence of candidate genes
annotated close to the associated signals.
Results
Identification of novel genetic loci associated with cartilage thickness
Genome-wideAssociation analysis of mJSW of the hip with genetic variants was performed in a
discovery set that included 13,013 individuals (see S1 Table and S1 Text for cohort specifics)with
data on ±2,5 million genotyped or HapMap Phase II imputed SNPs. We applied extensive quality
control measures (see S2 Table and S3 Table for details on quality control and exclusion criteria)
leaving a total of 2,385,183 SNPs available for association analyses. Genomic control inflation fac-
tors for the P values of the RS, TwinsUK, MrOS, and SOF GWAS were low (λ = 1.02, 1.01, 1.02
and 0.99 respectively), and the interquantile-quantile plot (S1 Fig) also indicated no residual pop-
ulation stratification due to cryptic relatedness, population substructure or other biases.
The discovery analysis yielded eighteen independent SNPs with suggestive evidence for
association (P<110−5) with mJSW, of which five (four genetic loci) met the genome-wide sig-
nificance threshold of P-value  510−8 (see Fig 1). The top SNPs from these eighteen loci were
selected for replication in additional 8,227 individuals from seven different cohorts.We
observed that six of the eighteen SNPs significantly replicated (P<0.05) with the same direction
of effect (see Table 1). When we combined discovery and replication results in a meta-analysis,
the five SNPs that met genome-wide significance in the discovery analysis becamemore signifi-
cant and another two SNPs that replicated in independent cohorts reached suggestive evidence
(P 110−6) for association in the combinedmeta-analysis.
Genetic Variants for Cartilage Thickness
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The top signal in the combinedmeta-analysis, rs1180992 (Table 1, Pcombined = 3.2x10-16), is
located in the intronic region of the previously OA associatedDOT1L gene. This variant is very
close to and in linkage disequilibriumwith rs12982744 (D’ = 1, r2 = 1), which was previously
found in association with mJSW and hip OA [1,8].
The DOT1L signal was followed in strength of association by rs2862851 (Pcombined =
5.2x10−11), which is annotated to the intronic region of TGFA (Fig 2A). Two variants near
RUNX2, rs10948155 and rs12206662, also reached genome-wide significance for association
with mJSW (Fig 2B). The two variants in the RUNX2 locus were weakly correlated (r2<0.2).
Conditional analysis, using GCTA, showed that both SNPs represented different signals (S4
Table). Finally, the last signal that reached genome-wide significancewas rs10471753, an inter-
genic variant closer to PIK3R1 (~450 Kb) than to SLC30A5 (~750Kb) (Table 1, Pcombined =
3.810−9).
Other suggestive signals for association with mJSW at a Pcombined 1x10−6 including signals
with significant replication were rs496547 (p = 1.5x10−7), a downstream gene variant located 3'
of TREH and, an intron variant annotated near SLBP (rs2236995; p = 9x10−7). All other addi-
tional signals selected in the discovery stage did not replicate.
Association of identified loci with hip OA and other musculoskeletal
phenotypes
We examined whether the five GWS and two suggestivemJSW loci were also associated with
hip OA in a total of 8,649 cases and>57,000 controls. Detailed description of the cohorts and
OA definitions is given in S1 Table. Table 2 shows the associations found with hip OA. We
observed that five of the seven identifiedmJSW loci were also associated with hip OA (p-
value<0.05). Apart from the knownDOT1L locus, the variant near TGFA was significantly
associated with hip OA (Table 2, P = 4.3x10−5). In addition, the SNP near SLBP and the two
Fig 1. Manhattan plot for association of mJSW in the discovery phase. The -log10 P values, for each of the 2.5 million tests
performed as part of the genome wide association of minimal joint space width of the hip (mJSW), plotted against their position per
chromosome. Full results of the discovery GWAS are accessible through www.glimdna.org. The gray solid horizontal line corresponds
to the genome-wide significant threshold (P = 5x10-8). The dotted grey line corresponds to the selection for replication threshold
(P = 1x10-5).
doi:10.1371/journal.pgen.1006260.g001
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SNPs near RUNX2 were associated with hip OA. One of the latter SNPs, rs10948155, is in high
LD with a variant (rs10948172, D’ = 0.95 and r2 = 0.90) previously found in association with
hip OA in males at borderline GWS level (2). However, in our study, rs10948155 was just mar-
ginally associated with hip OA in the overall analysis (Table 2, P = 0.021). We observed the sec-
ond variant in this genomic region, an intronic variant in RUNX2, rs12206662, to have a larger
effect size (β = 0.14, P = 1.1×10−4 r2 = 0.09 with rs10948172).
We further examined whether the identified loci were found associated with other pheno-
types in earlier reports (Table 3). Five of the seven identifiedmJSW SNPs mapped to loci that
have previously been associated with other bone-related phenotypes, primarily height. How-
ever, many of the identified height loci were not highly correlated with the mJSW signal
(Table 3). Additional adjustment for height did not have an effect on the described association
Table 1. Results from the minimal Joint Space Width genome-wide association study; discovery, replication and joint meta-analysis
SNP Chr Position Allele 1 Allele 2 Freq 1 Discovery Replication Joint meta-analysis Locus
Beta SE P-value Beta SE P-value Beta SE P-value
rs11880992 19 2127403 A G 0,40 0,096 0,013 9,1E-
14
0,091 0,029 1,5E-
03
0,095 0,012 3,2E-
16
DOT1L
rs2862851 2 70566310 T C 0,49 -0,070 0,013 2,9E-
08
-0,062 0,018 4,8E-
04
-0,067 0,010 5,2E-
11
TGFA
rs10948155 6 44795935 T C 0,67 0,081 0,013 1,2E-
09
0,045 0,019 1,5E-
02
0,069 0,011 1,5E-
10
SUPT3H-RUNX2
rs12206662 6 45484199 A G 0,07 -0,187 0,032 7,9E-
09
-0,093 0,035 7,3E-
03
-0,140 0,024 1,3E-
09
SUPT3H/RUNX2
rs10471753 5 67854708 c G 0,61 0,082 0,013 1,5E-
10
0,019 0,019 3,3E-
01
0,062 0,011 3,8E-
09
PIK3R1
rs496547 11 118081673 A T 0,34 -0,064 0,013 1,5E-
06
-0,046 0,022 3,8E-
02
-0,058 0,011 1,5E-
07
TREH-DDX6
rs2236995 4 1674340 T G 0,49 0,057 0,013 6,4E-
06
0,038 0,018 3,2E-
02
0,049 0,010 9,7E-
07
SLBP
rs717433 20 7786135 T C 0,76 0,067 0,015 8,0E-
06
0,058 0,033 8,3E-
02
0,065 0,014 1,4E-
06
HAO1
rs10495106 1 217017809 T C 0,94 0,119 0,026 6,2E-
06
0,055 0,037 1,3E-
01
0,096 0,021 6,4E-
06
TGFB2
rs6592847 11 78889654 A G 0,28 0,070 0,015 3,7E-
06
-0,014 0,056 8,1E-
01
0,065 0,015 9,5E-
06
NARS2
rs6429001 1 235495143 A G 0,83 0,078 0,017 3,1E-
06
-0,006 0,039 8,8E-
01
0,065 0,015 2,4E-
05
RIR2
rs13148031 4 145679788 A G 0,60 0,057 0,013 9,8E-
06
0,016 0,018 3,6E-
01
0,043 0,010 3,5E-
05
HHIP-GYPA
rs2061109 3 35380584 C G 0,50 0,057 0,013 8,8E-
06
0,003 0,030 9,2E-
01
0,048 0,012 3,7E-
05
ARPP-21
rs6437120 2 158493396 T C 0,50 -0,064 0,013 4,0E-
07
0,006 0,019 7,5E-
01
-0,043 0,011 4,5E-
05
ACVR1-UPP2
rs4837613 9 118349346 c G 0,49 -0,062 0,013 2,0E-
06
0,002 0,019 9,1E-
01
-0,041 0,011 1,1E-
04
ASTN2
rs11045356 12 20683368 A G 0,17 0,078 0,017 4,4E-
06
-0,052 0,036 1,5E-
01
0,059 0,016 1,8E-
04
PPE3A
rs2703529 17 74709369 A G 0,07 -0,114 0,024 2,9E-
06
0,006 0,034 8,6E-
01
-0,073 0,020 1,9E-
04
HRN3P3
rs7739938 6 139823110 A G 0,03 -0,314 0,065 1,1E-
06
-0,030 0,026 2,5E-
01
-0,069 0,024 3,9E-
03
CITED2
Chr: Chromosome; Allele 1: Modelled allele in the analysis; Allele 2: alternative allele; SE: standard error.
doi:10.1371/journal.pgen.1006260.t001
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with mJSW; they showed an independent, possibly pleiotropic effect, on both traits. A particu-
larly dense number of associations with different bone related phenotypes were present in the
RUNX2 5’ region, where variants have been associated to BMD [10], height [11], osteoarthritis
[2] and ossification of the spine [12]. Given the low LD between the variants underlying the dif-
ferent GWAS signals, it is likely that these represent independent associations.
Prioritization of genes underlying the genetic loci
We usedmultiple approaches that leverage different levels of information (e.g., gene expres-
sion, regulatory regions, published literature, mouse phenotypes) to prioritize candidate genes
at each mJSW locus. Table 4 shows the summarized results from these analyses. In addition to
the seven loci identified in the current study, we also analyzed five previously published loci for
hip OA [2].
First, we focused on two gene prioritizationmethods: (i) DEPICT, a novel tool designed to
identify the most likely causal gene in a given locus, and identify gene sets that are enriched in
the genetic associations [21], and (ii) GRAIL which uses existing literature to identify connec-
tions between genes in the associated loci [22]. The DEPICT analysis yielded seventeen signifi-
cantly prioritized genes (FDR>0.05), from which three genes were also significantly
prioritized in the GRAIL analysis (S5 Table and S6 Table). Next, using the OnlineMendelian
Inheritance in Man (OMIM) database (http://omim.org), we identified genes with mutations
implicated in abnormal skeletal growth in humans; for 50% of the loci, a skeletal syndrome
gene was present (S7 Table). Similarly, we investigated if any of the genes had a known bone
and cartilage development phenotype in mice. Very similar to the human phenotypes, the mice
knockouts of the same genes resulted in bone and cartilage phenotypes (http://mousemutant.
jax.org/) (S7 Table). Other supporting biological evidence that we gathered consisted of known
expression quantitative loci (eQTL) and nonsynonymous variants in LD (r2>0.6) with the lead
SNP of a locus (S8 Table and S9 Table), as well as expression in bone and cartilage tissue in
mice using data from the Jackson lab database (S7 Table).
To further explore which genes are possibly underlying the genetic associations identified in
this study, we analyzed gene expression in a paired set of non-lesioned and OA-lesioned
Fig 2. Regional association plot for the locus of rs2862851 rs12206662/rs10948155. SNPs are plotted by position in a
800-kb window versus association with mJSW (−log10 P) for A. rs2862851 (TGFA locus) and B. rs12206662/rs10948155
(SUPT3H/RUNX2 locus). The purple dot highlights the most significant SNP in discovery analysis. Blue peaks indicate
recombination rates. The SNPs surrounding the most significant SNP are color coded to reflect their LD with this SNP (from
pairwise r2 values from the HapMap CEU). Genes, exons and the direction of transcription from the University of California at
Santa Cruz genome browser are depicted. Plots were generated using Locus Zoom [9]
doi:10.1371/journal.pgen.1006260.g002
Table 2. Association of mJSW loci with Hip OA
SNP Locus Modelled allele Beta SE P-value
rs11880992 DOT1L A -0,064 0,016 6,4E-05
rs2862851 TGFA T 0,059 0,016 4,3E-05
rs10948155 SUPT3H-RUNX2 T -0,037 0,016 2,1E-02
rs12206662 SUPT3H-RUNX2 A 0,140 0,036 1,1E-04
rs10471753 PIK3R1 C 0,006 0,016 6,9E-01
rs496547 TREH-DOX6 A 0,006 0,016 7,1E-01
rs2236995 SLBP T -0,046 0,015 1,7E-03
SE: standard error
doi:10.1371/journal.pgen.1006260.t002
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cartilage samples of the RAAK study acquired from 33 donors at the time of joint replacement
surgery for primary OA [19]. We first examined which genes are expressed in a set of seven
human healthy cartilage samples (S7 Table). Additionally, we tested which of the genes located
in 1MB region surrounding the lead SNP were differentially expressed in OA-lesioned cartilage
versus non-lesioned cartilage of the same hip. Of the 152 genes that were selected, 129 genes
were represented on the array. Of those, 64 genes were significantly expressed in the cartilage
samples. For eight of the twelve loci, we found genes that were differentially expressed in OA
lesioned cartilage versus non-lesioned cartilage (Table 4, S10 Table). Differential expression in
cartilage healthy vs OA affected cartilagewas performed likewise (S10 Table), while additionally
adjusting for sex and age. Given the relatively small number of healthy samples (n = 7) with large
age range these data are less robust and we did not use these data in gene prioritization.
For each gene a prioritization score was computed, based on equally weighting of the ten
lines of evidence (Table 4). Following this approach, RUNX2 is highly likely to be the causal
gene associated with rs12206662 and rs10948155. Similar strong evidence is found for rs788748
(IGFBP3) and rs10492367 (PTHLH). In addition, suggestive evidence for a causal gene is found
for the following: rs10471753 (PIK3R1), rs835487 (CHST11), rs2862851 (TGFA), rs6094710
(SULF2), rs9350591 (COL12A1) and rs11177 (GNL3). However for some loci the current evi-
dence is ambiguous, suggestingmore than one gene as the potentially causal one; rs2236995
(FGFR3 or SLBP), rs11880992 (GADD45B orDOT1L) and rs496547(KMT2A or UPK2) (Table 4).
Exome sequencing of prioritised genes
In 2,628 individuals from the Rotterdam Study, exome sequencing was performed at a mean
depth of 55x. Of those, 2,050 individuals also had mJSW and hip OA phenotype data. Baseline
characteristics of those individuals were similar to the source population, mean age was 67.3
years, 57% of the individuals were female and mean of mJSWwas 3.81 mm (SD 0.82). Details
of the experimental procedure and variant calling are given in the supplementary material (S2
Text). Only the variants with a minimal allele count of three in the total population were
Table 3. Association of mJSW loci with previously reported phenotypes
SNP Locus Phenotype Reported SNP r2 with mJSW SNP
rs2862851 TGFA - -
rs11880992 DOT1L OA[1] rs12982744 1
Height[13] rs2523178 0,1
rs12206662 SUPT3H-RUNX2 OA[2] rs10948172 0,09
Height[13] rs10948222 0
BMD[10] rs117755164 0,04
OPLL[12] rs927485 0
rs10948155 SUPT3H-RUNX2 OA[2] rs10948172 0,84
Height[13] rs10948222 0
BMD[10] rs117755164 0,21
OPLL[12] rs92748 0
rs10471753 PIK3R1 - -
rs2236995 SLBP Height[14] rs2247341 0,6
rs496547 TREH-DDX6 Height[14] rs494459 0,36
Metabolite levels[15] rs507080 0,21
Vitiligo[16] rs638893 0,02
Celiac disease/ RA[17] rs10892279 0,36
SLE[18] rs4639966 0,21
doi:10.1371/journal.pgen.1006260.t003
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selected for analysis. Within the sixteen prioritized genes, a total number of 158 variants were
identified in the protein-coding region, of which 85 were non-synonymous and one was a
stop-gain mutation (Table 5, S11 Table).
We first performed a single variant test, where we tested each of the 86 variants changing
the amino-acid sequence for association with the mJSW trait (S11 Table). We observed four
nominal significant associations, with rare variants in SULF2, TGFA, RUNX2 and FGFR3.
None of these rare exonic variants explained the original association between the GWAS hit
and mJSW or hipOA when tested in a multivariate model (S12 Table). Next, we performed a
burden test (SKAT) [23], to investigate whether the cumulative effects of the variants present
in the sixteen selected genes were associated to mJSW, while adjusting for age and gender
(Table 5). We observed a nominal significance burden test (p<0.05) for TGFA, SULF2,
CHST11 and RUNX2 for mJSW. However, none of these findings reached significance after
correction for multiple testing.
mJSW associated SNPs in regulatory regions
For most of the loci, no obvious protein-coding variants were found that could explain the
associations. In previous studies it was shown that disease-associatedvariants are enriched in
regulatory DNA regions [24,25]. We therefore examined whether the identifiedDNA variants
(or SNPs in high LD) resided in chondrocyte and/or osteoblast specific enhancer regions, using
data from ENCODE and ROADMAP [26–28]. To this end, we compared CHIP-seq signals
from five different chromatin state markers (H3K4me3, H3K4me1, H3K36me3, H3K27me3,
H3K9me3) in chondroblasts and osteoblasts to four cell lines from another origin. Together,
these chromatin state markers identify promoter and enhancer activity in each of the cell lines.
With the exception of rs2862851,we observed that for all mJSW genetic loci, SNPs in high LD
were located in cell regulatory regions in chondroblast and/or osteoblast cells (see Fig 3 for an
overview and S13–S18 Tables for each locus).
Table 5. Association between protein coding variants identified by exome-sequencing and mJSW.
Variants Tested
Gene non-synonymous STOP Gained mJSW* Pvalue
CHST11 3 0,05
COL12A1 23 1 1,00
DOT1L 13 1,00
FGFR3 12 0,64
GADD45B 1 0,91
GNL3 5 0,64
IGFBP3 2 0,28
KMT2A 8 0,40
NCOA3 7 0,24
PIK3R1 3 0,80
PTHLH 0 NA
RUNX2 2 0,05
SLBP 1 0,16
SULF2 3 0,05
TGFA 1 0,04
UPK2 1 0,74
*A burden test was performed to test the association between the protein-coding variants in the candidate
genes and mJSW
doi:10.1371/journal.pgen.1006260.t005
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Discussion
Only a modest number of genetic variants has been successfully identified through genome-
wide association studies for OA This can in part be explained by the phenotypic heterogeneity
of OA. Therefore, we usedmJSW, a proxy for cartilage thickness in the hip joint, as one of the
structural components of joint health. An additional advantage of this phenotype is its continu-
ous nature, which increases power compared to a dichotomous trait, such as OA-status. We
identified six independent loci associated with cartilage thickness in the hip joint, of which four
surpassed genome-wide significance (TGFA, PIK3R1, SUPT3H-RUNX2,DOT1L) and two were
suggestive for association with mJSW (SLBP/FGFR3,TREH-DDX6). Four of these loci (TGFA,
SUPT3H-RUNX2,DOT1L and FGFR3) were also associated with hip OA.
The fact that we were able to identify six loci with the current sample size (13K individuals
in the discovery) indicates that cartilage thickness is a phenotype providing a better yield in
number of discoveries than the efforts ran with traditional composite radiographic scores. As a
comparison, the largest GWAS study up to now, arcOGENwith 7,4K cases and 11K controls
as discovery, yielded one locus in the overall analysis, and seven additionally in a number of
stratified analyses. Interestingly, in the current manuscript we report on rs10948155, which is
in high LD (r2>0.8) with a locus from arcOGENwhich was only marginally associated (p
below genome-wide significance threshold) with OA in males only [2]. By using a cartilage spe-
cific endophenotype, evidence for this locus is elevated here to genome-wide significance in the
total population, underscoring the increased power whenmore specific endophenotypes are
used. Endophenotypes are quantifiable biological traits intermediate in the causal chain
between genes and diseasemanifestation (in this case osteoarthritis). JSW can be precisely
measured throughout the life of individuals [7] and also displays variation in normal subjects.
Therefore, mJSWmay be more tractable for the genetic dissection of OA.
Across the cohorts in this manuscript, mJSW has beenmeasured in different ways, using
both hand measured JSW on radiographs as well as (semi) automatic software which could
Fig 3. mJSW and OA associated variants are co-localized with potential gene regulatory markers. We
examined the epigenetic histone marks in Chondrogenic cells, osteoblasts, hMSC, K562, HUVEC, HeLA and
NHEK cells. This heatmap of the percentage of variants in gene regulatory regions (enhancer/promoter associated
regions) in high LD (r2 >0.8) with lead GWAS SNP. Enrichment was calculated according [25].
doi:10.1371/journal.pgen.1006260.g003
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have added some noise to the overall meta-analysis. Future cross-calibration of JSWmeasure-
ments might aid in a more precise measurement and additional power to pick up genetic loci.
To the best of our knowledge, we are the first to scrutinize exome variants in relation to OA
identified by large scale re-sequencing.We did not find low frequency exonic variants in any of
the prioritized genes that could explain the observed associations with mJSW. We do have to
keep in mind that the power of the exome sequencing effort is smaller than the original discov-
ery analysis. We were unable to examine variants with allele frequencies below 0,07%. In addi-
tion, for rare or low allele frequencies, we only had power to detect relatively large effect sizes.
For example, we had 80% power to detect a beta of 0,7 mm (almost 1SD) difference for a vari-
ant with 1% allele frequency. However, we tested all of the discovered exome variants in a mul-
tivariate analysis, and found that the novel identified rare exome variants did not affect the
association between the GWAS-identified variants and mJSW in the same sample. This sug-
gests that the associations betweenmJSW and the identified SNPs are not explained by rare
exonic variants and likely exert their effects through regulation of expression. Indeed, support-
ing this hypothesis, we found that many these variants (or SNPs in LD) were annotated in
regions that were annotated as regulatory active in chondroblastic and/or osteoblastic cells.
However, more work is needed to examine the exact biologicalmechanism underlying the
identified genetic loci.
TGFA (Transforming Growth Factor Alpha, rs2862851)was the strongest novel locus asso-
ciated with cartilage thickness and hip OA. TGFA has been suggested to be involved in endo-
chondral bone formation in mice, specifically the transition from hypertrophic cartilage to bone
[29]. Recent,TGFA has also been implicated in the degeneration of articular cartilage during OA
in rats [30]. Our results now imply a relationship betweenTGFA and human OA. In addition to
the genetic association, we also show that TGFA expression is higher in human OA affected ver-
sus non-lesioned cartilage, possibly indicating that TGFA has a role in cartilage remodeling.
Functional characterization of the TGFA- associated locus by an examination of the histone
methylation marks representing promoter or enhancer activity, did not reveal an obvious expla-
nation for the functional impact of the SNP. However, the examined histone mark data represent
unstimulated cells, and it is anticipated that the promoter and enhancer activity change upon
stimulation of the cells. It is becomingmore clear that effects of SNPs can be stimulus and context
dependent, as has recently been shown for human monocytes, where many regulatory variants
display functionality only after pathophysiological relevant immune stimuli [31].
The identified SUPT3H-RUNX2 locus contains two variants, rs12206662 and rs10948155,
which are partially independent of each other. Where rs12206662 is located in the first intron
of the RUNX2 gene near the second transcription start site (the so-called P2 promoter),
rs10948155 is locatedmore than 500kb away from RUNX2 betweenCDC5L and SUPT3H.
However, rs10948155 is in high linkage disequilibriumwith SNPs near in the P2 promoter and
SNPs located in chondroblast specific enhancer regions (S16 and S17 Tables).Possibly, these
enhancer regions regulate RUNX2 gene expression during endochondral differentiation.
RUNX2 (Runt-related transcription factor 2) is a master transcription factor for controlling
chondrocyte hypertrophy and osteoblast differentiation [32]. Previous genome-wide associa-
tion studies have identified variants in the SUPT3H-RUNX2 locus associated with other bone
and cartilage related phenotypes including height [14], bone mineral density [10] and ossifica-
tion of the posterior longitudinal ligament of the spine [12]. All these previously published loci
are independent of the two mJSW SNPs identified in the current study. We hypothesize that
the SNPs are located in long-range enhancers, which regulate RUNX2 gene expression during
endochondral differentiation via a chromatin-loop mediating protein.
We have also identified rs10471753, with PIK3R1 (Phosphoinositide-3-Kinase, Regulatory
subunit 1 alpha) as the closest and strongest prioritized gene, related to rs10471753 associated
Genetic Variants for Cartilage Thickness
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with mJSW. Mutations in this gene are known to cause the SHORT syndrome, which is a rare
multisystem disease with several manifestations including short stature, hernias, hyper extensi-
bility and delayed dentition [33].Taken together with the fact that PIK3R1 is differentially
expressed in OA affected cartilage, these results identify PIK3R1 as the most likely causal gene.
Another possibility is that not PIK3R1 but rather a long-non-coding RNA (lncRNA), lnc-
PIK3R1-4:1, is causal, since a variant in LD with the lead SNP is located in the predicted tran-
scription start site of this lncRNA potentially affecting its expression. Although conserved in
mice and zebrafish, thus far no function has been ascribed to this lncRNA [34].
We confirmed a locus previously associated with cartilage thickness, theDOT1L locus. Our
identified SNP, rs11880992 is in high LD with the previously reported SNP rs129827744, and
both are associated with cartilage thickness and hip OA [1]. Despite the previously presented
suggestive evidence for involvement of DOT1L in chondrogenic differentiation,DOT1L did
not receive a high score in our systematic prioritization study; the geneGADD45B, located in
the region 500Kb downstream of the lead SNP, received a similar score. GADD45B is a tran-
scriptional co-factor for C/EBP-β, a master regulator of chondrocyte differentiation [35]. Thus,
it remains unclear which gene or genes in this locus contribute to the cartilage phenotype. Fur-
ther research is needed to determine whetherDOT1L is the true causal gene in this locus.
Our analyses suggest that the majority of prioritized genes in hip OA associated loci are
involved in cartilage and bone developmental pathways; including TGFA, RUNX2, FGFR3,
PTHLH, COL12A1 and others that seem to affect bone and/or cartilage development such as
PIK3R1 and KMT2AWe hypothesize that the mJSW and OA associated variants influence
gene expression regulation. The dysregulation of these genes and mechanisms during develop-
ment may, later in life, result in an increased risk for OA.
The identifiedmJSW SNPs are associatedwith hip OA, but not with knee OA. We have ana-
lysed the identified SNPs also for association with knee OA in the TREAT-OA meta-analysis
dataset [36], but found no association. This observation fits in the overall finding that many of
the identified genetic loci for OA seem to be site-specific [37], and support the hypothesis that
the aetiology of OA is different in each joint. Nevertheless, this observation can still be a result
of low power in the GWAS studies that have been done for OA till now [38], and final conclu-
sions on this aspect cannot be drawn at this point.
This is the first report linking TGFA to human OA most likely by affectingmJSW. It may
serve as a new target for future therapies. We have identifiedmultiple mJSW associated loci
which have previously been associated with other bone and cartilage related phenotypes such
as bone mineral density and height, displaying a possible pleiotropic effect for the analysed
traits. It will be important to understand how mJSW and OA associated variants can affect the
developmental processes that regulate morphometry of the hip joint, including the formation
of articular cartilage. Therefore further expression and functional studies are warranted of
genes identified to be associated with hip OA phenotypes.
Materials and Methods
Ethics statement
The participating studies were approved by the medical ethics committees of all participating
centres, and all participants gave their written informed consent before entering the study
Discovery GWAS, replication and meta-analysis
We conducted genome-wide association studies of mJSW for each cohort of the discovery
stage: Rotterdam Study I (RS-I), Rotterdam Study II (RS-II), TwinsUK, SOF and MrOS using
standardized age-, gender and population stratification (four principal components) adjusted
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residuals from linear regression. Cohort description and details of the single GWAS studies are
given in S1 Text and S1 Table. The 6 cohorts used in the discovery stage were combined in a
joinedmeta-analysis using inverse variance weighting withMETAL [39]. Genomic control cor-
rection was applied to the standard errors and P-values before meta-analysis. SNPs with a P
value< = 5×10−6 were selected for replication. The top SNPs for each independent locus were
taken for replication in seven studies: the Genetics of Osteoarthritis and Lifestyle (GOAL)
study, the Chingford study, CHECK (Cohort Hip & Cohort Knee), Genetics osteoARthritis
and progression (GARP) study, the Genetics of GeneralizedOsteoarthritis (GOGO), the John-
ston County Osteoarthritis Project (JoCo) and additionally the Nottingham OA case-control
study for association with Hip OA (see Supplemental material for detailed information of the
cohorts). Association of the SNPs with mJSWwas additionally adjusted for height to test its
independence. Secondary analyses included: association of the top SNPs with hip OA using
logistic regression analysis (age and gender adjusted and by study centres an/or relatedness
when it was pertinent).We used conditional analyses to investigate whether there are any inde-
pendent signals in the identified associated loci, which were implemented using GCTA-COJO
analysis [40].
Phenotype description of minimal Joint Space width (mJSW)
The mJSWwas assessed at pelvic radiographs in anteriorposterior position. The mJSWwas
measured in mm, along a radius from the center of the femoral head, and defined as the short-
est distance found from the femoral head to the acetabulum.Within the Rotterdam Study, we
used a 0.5 mm graduatedmagnifying glass laid directly over the radiograph to measure the
minimal joint space width of the hip joints [41]. Within SOF and MrOS, a handheld caliper
and reticule was used to measuredmJSW to the nearest 0.1mm between the acetabular rim and
proximal head of the femur [42]. For CHECK,mJSWwas measured semi-automatic with the
Software tool HOLY [43].
Phenotype description of radiographic hip OA
Radiographic hip OA was defined in the RS-I, RS-II, RSIII, Twins-UK, Chingford, and JoCo
studies using Kellgren and Lawrence (K/L) scores. Hip OA cases were defined as a K/L score 2
on either side of the hip or THR due to OA. Hip OA controls were defined as no THR for OA
and K/L score 1 and JSN 1. In MrOS and SOF cohorts, radiographic hip OA case-control
was defined by a modifiedCroft grade, as previously described [44], where cases were defined as
a Croft score 2 on either side of the hip or THR due to OA and controls were defined as a
Croft score 1 on both sides of the hip and no THR.Hip OA cases in the GOAL and Notting-
ham OA studies were defined by having THR, and controls were radiographically free of hip OA,
as previously described [45]. In GARP, hip osteoarthritiswas defined as pain or stiffness in the
groin and hip region on most days of the precedingmonth in addition to femoral or acetabular
osteophytes or axial joint space narrowing on radiography or prosthesis due to osteoarthritis. In
GOGO, hip OA was defined as KL grade> = 2, or minimal joint space width< = 2.5 mm, or the
combination of joint space narrowing grade> = 2 and any osteophyte of grade> = 1, or history
of joint replacement for OA. In JoCo, hip OA cases were defined as KL grade> = 2 or THR in at
least one hip. Hip OA controls were defined as KL grade< = 1 in both hips.
Gene prioritization analysis
We have used several available tools and publicly available databases to prioritize genes in
known and newly discovered osteoarthritis associated regions. Locus gene sets were con-
structed by taking a region of 500 Kb upstream and 500Kb downstream of the lead SNP of that
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locus.We analysed 152 genes in 13 independent loci associated with minimal joint space width
in the hip joint (mJSW) for 7 loci, hip OA for 4 loci, total joint replacement (TJR) for 1 locus
and total hip replacement (THR) for 1 locus [2]. We analysed the following biological evidence
for each gene at all loci; Nearest located genes: Taken from the UCSC genome browser,
GRCh37/hg19 [46]. DEPICT gene prioritization: Data-driven Expression-Prioritized Integra-
tion for Complex Traits, a novel tool designed to identify the most likely causal gene in a given
locus and to gene sets that are enriched in the genetic associations [21]. DEPICT was used to
prioritize genes in a 1 MB region around the found SNPs that were significant associated with
the osteoarthritis phenotype, taking a region of 500 Kb upstream and 500Kb downstream of
the lead SNP of that locus. Gene prioritization analysis was performed to directly investigate
functional similarities among genes from different associated regions, significancewas defined
by false discovery rate (FDR 5%). GRAIL gene prioritization: Gene Relationships Across
Implicated Loci (GRAIL), was used to determine connectively between genes across OA impli-
cated loci based on literature associations [22]. A GRAIL analysis was performed on 10 inde-
pendent OA associated loci, based on existing literature in PubMed till August 2014. Mouse
gene expression and phenotype: For each investigated gene, expression in mouse bone and/or
cartilage tissue during several developmental stages as well as for adult tissue was determined
using data from the Jackson lab database (http://www.informatics.jax.org/). In addition mouse
phenotype data was also obtained for each gene. OMIM phenotype: Using the OnlineMende-
lian Inheritance in Man (OMIM) database we examined which genes were involved in abnor-
mal skeletal growth syndromes whenmutated (http://omom.org). Expression quantitative trait
loci: eQTL information was taken from the Blood eQTL browser (http://genenetwork.nl/
bloodeqtlbrowser/) and the eQTL browser (http://www.ncbi.nlm.nih.gov/projects/gap/eqtl/
index.cgi) using the lead SNP in each locus [20]. Non-synonymous variants: Last we deter-
mined if there were any nonsynonymous variants in LD (r2>0.06) with the lead SNP of a
locus, using HaploReg V2 and the SNP Annotation and Proxy Search (SNAP) tools [47,48].
For each gene we assigned a score based on equally weighted lines of evidence.
Human cartilage gene expression
We have used cartilage samples from the RAAK study to study gene expression in preserved
and affected cartilage from individuals undergoing joint replacement [19]. The ongoing
Research Arthritis and Articular Cartilage (RAAK) study is aimed at the biobanking of blood,
joint materials (cartilage, bone and where available ligaments of knees and hips) and bonemar-
row stem cells (hip joints only) of patients and controls in the LeidenUniversity Medical Cen-
ter and collaborating outpatient clinics in the Leiden area. At the moment of collection (within
2 hours following surgery) tissue was washed extensively with phosphate buffered saline (PBS)
to decrease the risk of contamination by blood, and cartilage was collected of the weight-bear-
ing area of the joint. Cartilage was classifiedmacroscopically and collected separately for
macroscopically OA affected and preserved regions. Classificationwas done according to pre-
defined features for OA related damage based on color/whiteness of the cartilage, based on sur-
face integrity as determined by visible fibrillation/crack formation, and based on depth and
hardness of the cartilage upon sampling with a scalpel. During collectionwith a scalpel, care
was taken to avoid contamination with bone or synovium. Collected cartilage was snap frozen
in liquid nitrogen and stored at -80°C prior to RNA extraction. Tissues have been stored tai-
lored to apply staining and immunohistochemistry (IHC). Furthermore, DNA and RNA have
been isolated from the preserved and affected areas of the respective tissues in order to apply
genetic, transcriptomic and epigenomic profiling with respect to the OA pathophysiological
process.
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After in vitro transcription, amplification, and labeling with biotin-labeled nucleotides (Illu-
mina TotalPrep RNA Amplification Kit) Illumina HumanHT-12 v3 microarrays were hybrid-
ized. Sample pairs were randomly dispersed over the microarrays, however each pair was
measured on a single chip. Microarrays were read using an Illumina Beadarray 500GX scanner
and after basic quality checks using Beadstudio software data were analyzed in R statistical pro-
gramming language. Intensity values were normalized using the “rsn” option in the Lumi-
package and absence of large scale between-chip effects was confirmed using the Globaltest-
package in which the individual chip numbers were tested for association to the raw data. After
removal of probes that were not optimally measured (detectionP>0.05 in more than 50% of
the samples) a paired t-test was performed on all sample pairs while adjusting for chip (to
adjust for possible batch effects) and using multiple testing correction as implemented in the
“BH” (Benjamini and Hochberg) option in the Limma-package. Analyses for differential
expression betweenOA and healthy and between preserved and healthy cartilage was per-
formed likewise, adjusting in addition for sex and for age.
Exome sequencing
Exome sequencing was performed in 2628 individuals from the Rotterdam Study the average
mean coverage was 55x, corresponding to approximately 80% of the targeted regions covered
by at least 20 reads. The exome sequencing was performed in house (HuGe-F, www.glimDNA.
org). Details of the technical procedure and variant calling are given in S2 Text. We tested the
exome variants for association with mJSW and/or hip OA in two ways. Each individual variant
was tested for association with mJSW using the single variant option within RV-test, while
adjusting for age and sex. In addition, we did a burden test for each of the selected genes by
using SNP-set kernel association test (SKAT-O). SKAT aggregates individual score test statis-
tics of SNPs in a SNP set and computes SNP-set level p-values for a gene [23].
Visualization of the regulatory landscape of mJSW associated loci
For each of the top mJSWGWAS associated SNPs the LD region was determined using the
1000G Phase 1 population using the Haploreg tool [47]. The LD threshold was set at r20.8.
For each of these SNPs it was determined if the variant was located in a potential enhancer
region using the Roadmap consortium reference epigenomes data set [27]. Heatmaps were
constructed by calculating the percentage of variants in LD with the top mJSWGWAS found
SNP located in enhancer regions as defined by the Roadmap epigenome chromatin states. The
reference epigenomes were downloaded from the official data portal accompanying [27]. Refer-
ence epigenome data was used frommesenchymal stem cell derived chondrocyte cultured
cells, Osteoblast, Bonemarrow derived culturedmesenchymal stem cells, K562, HUVEC,
HeLA and NHEK cells. Reference epigenomes were chromatin state models based on ChIPseq
data of 5 core histone marks (H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3) and
an additional H3K27ac histone mark, the Roadmap expanded 18-state model.
ChIPseq data of mesenchymal stem cell derived chondrocyte cultured cells, and bone mar-
row derived culturedmesenchymal stem cells were generated by the NHI roadmap epige-
nomics project [28]. ChIPseq data of, Osteoblast, K562, HUVEC, HeLA and NHEK cells were
generated by the ENCODE consortium [26]. All data and annotation tracks were downloaded
through the UCSC genome browser table tool. Visualization of all ChIPseq annotation and
roadmap full epigenomes tracks was done through the UCSC genome browser on GRCh37/
hg19. Heatmaps were plotted in R using the CRAN software packages gplots and Rcolor-
Brewer. Enrichment was calculated according to methods described in Trynka et al [25].
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